Repligen to Present at JMP Securities Healthcare Conference 2012
Friday, July 13, 2012 11:00 a.m. EDT
WALTHAM, Mass.--(BUSINESS WIRE)-- Repligen Corporation (RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present a corporate update at the JMP Securities Healthcare Conference 2012 in New York. The Repligen presentation is scheduled for Friday, July 13, at 11:00 a.m. EDT.
A live webcast and subsequent archived replay of the presentation will be available through the Investors section of Repligens corporate website at www.repligen.com. To access the live webcast, please log on through the Companys website approximately 15 minutes prior to the presentation.
About Repligen Corporation
Repligen Corporation is a leading supplier of critical biologic products used to manufacture biologic drugs. Repligen also applies its expertise in biologic product development to RG1068, a synthetic hormone being developed as a novel imaging agent for the diagnosis of a variety of pancreatic diseases. In addition, the Company has two central nervous system (CNS) rare disease programs in Phase 1 clinical trials. Repligens corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like believe, expect, may, will, should, seek, or could and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements, except as required by law.
Sondra S. Newman, 781-419-1881
Director Investor Relations
Source: Repligen CorporationCopyright Business Wire 2012